



This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	MicroRNA-23b (miR-23b)	Patient sample and mouse studies suggest increasing miR-23b signaling could help treat prostate cancer. In patient samples, miR-23b expression was lower in prostate cancer tissue than in benign prostatic hyperplasia and normal tissue. In a mouse xenograft model of prostate cancer, intratumoral delivery of miR-23b decreased tumor growth compared with delivery of control miRNA. Next steps could include evaluating vehicles for targeted delivery of miR-23b in prostate cancer models.	Patent and licensing status unavailable	Majid, S. et al. Cancer Res.; published online Oct. 16, 2012; doi:10.1158/0008-5472.CAN-12-2181 Contact: Rajvir Dahiya, San Francisco VA Medical Center and University of California, San Francisco, Calif. e-mail: rdahiya@urology.ucsf.edu
		SciBX 5(44); doi:10.1038/scibx.2012.1157 Published online Nov. 8, 2012		